/DCPH

DCPH Stock - Deciphera Pharmaceuticals, Inc.

Q: What is the analyst price target for DCPH?

Analyst price target information is not currently available for DCPH.

Q: What is DCPH's market cap?

Market capitalization information is not currently available for DCPH.

Healthcare|Drug Manufacturers - Specialty & Generic|NASDAQ

$25.59+0.08%

+$0.02 (+0.08%) • Jun 10

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-7.0%upside

Target: $23.80

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for DCPH

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2019

FY2020

FY2021

FY2022

FY2023

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.18

52W High$25.61

52W Low$9.90

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2023	FY2022	FY2021	FY2020	FY2019
Revenue	$163.36M	$134.04M	$96.15M	$42.09M	$25.00M
Gross Profit	$159.62M	$125.27M	$93.22M	$41.86M	$24.17M
Gross Margin	97.7%	93.5%	97.0%	99.5%	96.7%
Operating Income	$-210,958,000	$-182,722,000	$-300,077,000	$-271,190,000	$-200,726,000
Net Income	$-194,942,000	$-178,931,000	$-296,837,000	$-266,489,000	$-191,493,000
Net Margin	-119.3%	-133.5%	-308.7%	-633.2%	-766.0%
EPS	$-2.29	$-2.37	$-5.11	$-4.78	$-4.47

Company Overview

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Visit Website

Rating Distribution

Strong Buy

Buy / Outperform

80%

Hold / Neutral

20%

Sell / Underperform

Analyst Consensus🟢 Bullish

4 Bullish1 Neutral/Bearish

Price Targets

$21

Average Target

↓ 17.3% Downside

Now

$14

Low

$21

Average

$25

High

Based on 6 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
November 20th 2023	JP Morgan	Resumed	Neutral	$14
October 30th 2023	Piper Sandler	Upgrade	Overweight	$23
August 10th 2023	Stifel	Upgrade	Buy	$20← $14
January 4th 2023	Guggenheim	Upgrade	Buy	$22
August 29th 2022	Cowen	Initiation	Outperform	$25
August 5th 2022	JMP Securities	Upgrade	Mkt Outperform	$23

Earnings History & Surprises

DCPH

Beat Rate

60%

Last 20 quarters

Avg Surprise

+3.5%

EPS vs Estimate

Beats / Misses

12/7

1 met exactly

Latest EPS

$-0.52

Q2 2024

EPS Surprise History

Q3 22

+7.7%

$-0.60vs$-0.65

Q4 22

+3.5%

$-0.55vs$-0.57

Q1 23

-5.3%

$-0.60vs$-0.57

Q2 23

0.0%

$-0.60vs$-0.60

Q3 23

+8.1%

$-0.57vs$-0.62

Q4 23

+3.3%

$-0.58vs$-0.60

Q1 24

+6.9%

$-0.54vs$-0.58

Q2 24

+5.5%

$-0.52vs$-0.55

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q2 2024	May 10, 2024	$-0.55	$-0.52	+5.5%	✓ BEAT
Q1 2024	Feb 6, 2024	$-0.58	$-0.54	+6.9%	✓ BEAT
Q4 2023	Oct 30, 2023	$-0.60	$-0.58	+3.3%	✓ BEAT
Q3 2023	Aug 9, 2023	$-0.62	$-0.57	+8.1%	✓ BEAT
Q2 2023	May 3, 2023	$-0.60	$-0.60	0.0%	= MET
Q1 2023	Feb 7, 2023	$-0.57	$-0.60	-5.3%	✗ MISS
Q4 2022	Nov 3, 2022	$-0.57	$-0.55	+3.5%	✓ BEAT
Q3 2022	Aug 4, 2022	$-0.65	$-0.60	+7.7%	✓ BEAT
Q2 2022	May 4, 2022	$-0.84	$-0.80	+4.8%	✓ BEAT
Q1 2022	Feb 8, 2022	$-1.49	$-1.51	-1.3%	✗ MISS
Q4 2021	Nov 2, 2021	$-1.29	$-1.37	-6.2%	✗ MISS
Q3 2021	Aug 3, 2021	$-1.15	$-1.21	-5.2%	✗ MISS
Q2 2021	May 4, 2021	$-1.08	$-1.06	+1.9%	✓ BEAT
Q1 2021	Feb 9, 2021	$-1.16	$-1.10	+5.2%	✓ BEAT
Q4 2020	Nov 5, 2020	$-1.32	$-1.13	+14.4%	✓ BEAT
Q3 2020	Aug 4, 2020	$-1.34	$-1.20	+10.4%	✓ BEAT
Q2 2020	May 5, 2020	$-1.28	$-1.36	-6.3%	✗ MISS
Q1 2020	Mar 9, 2020	$-1.13	$-1.31	-15.9%	✗ MISS
Q4 2019	Nov 4, 2019	$-1.19	$-1.28	-7.6%	✗ MISS
Q3 2019	Aug 2, 2019	$-1.06	$-0.56	+47.2%	✓ BEAT

Frequently Asked Questions about DCPH

What is DCPH's current stock price?

Deciphera Pharmaceuticals, Inc. (DCPH) is currently trading at $25.59 per share. The stock has moved +0.08% today.

What is the analyst price target for DCPH?

The average analyst price target for DCPH is $23.80, based on 1 analyst.

What sector is Deciphera Pharmaceuticals, Inc. in?

Deciphera Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the NASDAQ exchange.

What is DCPH's market cap?

Deciphera Pharmaceuticals, Inc. has a market capitalization of $2.21 billion, making it a mid-cap company.

Does DCPH pay dividends?

No, Deciphera Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.